ALDEYRA THERAPEUTICS, INC. — Operating Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/e621c70f-0d1f-40b0-bdad-925b67fa0530/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-35.3M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-083012 |
| FY 2024 | $-60.1M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-030102 |
| FY 2023 | $-42.8M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-027933 |
| FY 2022 | $-62.7M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-006998 |
| FY 2021 | $-56.2M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-004111 |
| FY 2020 | $-36.4M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-012501 |
| FY 2019 | $-63.1M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-010493 |
| FY 2018 | $-39.7M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-006997 |
| FY 2017 | $-22.5M | 2017-01-01 – 2017-12-31 | evidence 0001193125-18-102077 |
| FY 2016 | $-18.7M | 2016-01-02 – 2016-12-31 | evidence 0001193125-18-102077 |
| FY 2015 | $-12.0M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-523952 |
| FY 2014 | $-7.3M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-101703 |
| FY 2013 | $-20.5M | 2004-08-13 – 2014-03-31 | evidence 0001193125-14-233411 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).